Literature DB >> 22086575

Validation of MagedanzSCORE as a predictor of mediastinitis after coronary artery bypass graft surgery.

Michel Pompeu Barros de Oliveira Sá1, Evelyn Soares Figueira, Cecília Andrade Santos, Omar Jacobina Figueiredo, Renato Oliveira Albuquerque Lima, Fábio Gonçalves de Rueda, Rodrigo Renda de Escobar, Alexandre Magno Macário Nunes Soares, Ricardo de Carvalho Lima.   

Abstract

OBJECTIVE: The aim of this study is to evaluate the applicability of a new score for predicting mediastinitis - MagedanzSCORE - in patients undergoing coronary artery bypass graft (CABG) surgery in the Division of Cardiovascular Surgery of Pronto Socorro Cardiológico de Pernambuco - PROCAPE.
METHODS: Retrospective study involving 500 patients operated between May/2007 and April/2010. The registers contained all the information used to calculate the MagedanzSCORE. The outcome of interest was mediastinitis. We calculated sensitivity, specificity, positive predictive value, negative predictive value, concordance and accuracy. The accuracy of the model was evaluated by ROC (receiver operating characteristic) curve.
RESULTS: The incidence of mediastinitis was 5.6%, with a lethality rate of 32.1%. In univariate analysis, the five variables of the MagedanzSCORE were predictors of postoperative mediastinitis: chronic obstructive pulmonary disease (OR 6.42; 95.0% CI 2.76-14.96; P<0.001), obesity (OR 3.06; 95.0% CI 1.32-7.09; P=0.009), surgical reintervention (OR 82.40; 95.0% CI 30.40-223.30; P<0.001), multiple transfusion (OR 3.33; 95.0% CI 1.52-7.29; P=0.003) and stable angina class IV or unstable (OR 2.59; 95.0% CI 1.19-7.64; P=0.016) according to Canadian Cardiovascular Society. The score had a sensitivity of 96.4%, specificity of 90.0%, positive predictive value of 36.5%, negative predictive value of 99.8% and 90.4% concordance. The accuracy measured by the area under the ROC curve was 96.2% (95.0% CI 94.5%-97.9%).
CONCLUSIONS: The MagedanzSCORE proved to be a simple and objective index, revealing a satisfactory predictor of development of postoperative mediastinitis in patients undergoing CABG surgery at our institution.

Entities:  

Mesh:

Year:  2011        PMID: 22086575     DOI: 10.5935/1678-9741.20110013

Source DB:  PubMed          Journal:  Rev Bras Cir Cardiovasc


  5 in total

Review 1.  Sternal wound tuberculosis following cardiac operations: a review.

Authors:  Shi-Min Yuan
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Jul-Aug

2.  Predictors of Mediastinitis Risk after Coronary Artery Bypass Surgery: Applicability of Score in 1.322 Cases.

Authors:  Fabiana Dos Santos Oliveira; Letícia Delfino Oliveira de Freitas; Eneida Rejane Rabelo-Silva; Laura Maggi da Costa; Renato Abdala Karam Kalil; Maria Antonieta Pereira de Moraes
Journal:  Arq Bras Cardiol       Date:  2017-08-17       Impact factor: 2.000

3.  Pre-validation Study of the Brazilian Version of the Disruptions in Surgery Index (DiSI) as a Safety Tool in Cardiothoracic Surgery.

Authors:  Vinicius José da Silva Nina; Fabio B Jatene; Nick Sevdalis; Omar Asdrúbal Vilca Mejía; Carlos Manuel de Almeida Brandão; Rosangela Monteiro; Luiz Fernando Caneo; Paula Gobi Scudeller; Augusto Dimitry Mendes; Vinícius Giuliano Mendes; Bellkiss Wilma Romano
Journal:  Braz J Cardiovasc Surg       Date:  2017 Nov-Dec

4.  Performance of a novel risk model for deep sternal wound infection after coronary artery bypass grafting.

Authors:  Pedro de Barros E Silva; Marco Antonio Praça Oliveira; Marcelo Arruda Nakazone; Marcos Gradim Tiveron; Valquíria Pelliser Campagnucci; Bianca Maria Maglia Orlandi; Omar Asdrúbal Vilca Mejia; Jennifer Loría Sorio; Luiz Augusto Ferreira Lisboa; Jorge Zubelli; Sharon-Lise Normand; Fabio Biscegli Jatene
Journal:  Sci Rep       Date:  2022-09-07       Impact factor: 4.996

Review 5.  Latitude of the study place and age of the patient are associated with incidence of mediastinitis and microbiology in open-heart surgery: a systematic review and meta-analysis.

Authors:  M Abdelnoor; Ø A Vengen; O Johansen; I Sandven; A M Abdelnoor
Journal:  Clin Epidemiol       Date:  2016-06-02       Impact factor: 4.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.